Lucyd, Inc LUCY PHARMA
Company Overview
Lucyd, Inc develops and sells smart eyewear in North America. It offers smart eyewear products to enable wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform smartphone tasks hands-free, as well as prescription eyeglasses, ready-to-wear sunglasses, safety glasses, and sport glasses under the Lucyd Lyte, Lucyd Armor, Nautica, Eddie Bauer, and Reebok brand names. The company also provides Lucyd app for unlimited ChatGPT interactions and tech support. It sells its products through e-commerce and a network of retail stores of resellers. The company was formerly known as Innovative Eyewear, Inc. and changed its name to Lucyd, Inc in October 2025. Lucyd, Inc was founded in 2019 and is headquartered in North Miami, Florida.
Why Investors Should Care
Revenue has grown at a 40.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $2.66M (+62.6% YoY); net profit $-7.59M.
- Trailing 12 Months Year-on-year growth — revenue +74.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 40.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 40.11% |
| 1 Year: | 74.50% |
Stock Price Performance
| 1 Year: | -56.62% |
| 6 Months: | -18.92% |
| 3 Months: | -5.28% |
| 1 Month: | +20.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)50.46 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 40.1% over 5 years.
CONS
- Trading 60.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LUCY Lucyd, Inc PHARMA | 0.87 | -0.75 | $7.49M | 0.00% | - | -84.58% | 40.11% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 127.03K | 171.03K | 236.02K | 204.74K | 151.96K | 144.92K | 169.93K | 221.88K | 383.47K | 308.68K | 253.60K | 454.50K | 579.23K | 668.13K | 773.56K |
| Gross Profit | - | 32.66K | 40.81K | 74.39K | 43.25K | 22.86K | 10.29K | -29.82K | 80.34K | 6.95K | 55.18K | 59.34K | 220.53K | -12.66K | 244.84K | 175.44K |
| Net Income | -221.71K | -536.60K | -1.10M | -1.21M | -1.19M | -1.40M | -1.43M | -1.29M | -1.55M | -1.97M | -1.95M | -1.72M | -1.78M | -2.11M | -1.84M | -2.31M |
| Diluted EPS | - | - | - | - | -0.20 | -0.21 | -0.19 | -2.56 | -2.08 | -2.59 | -1.87 | -0.99 | -0.72 | -0.66 | -0.38 | -0.37 |
| R&D Expense | - | 19.13K | 9.22K | 35.81K | 52.56K | 304.69K | 151.17K | 197.48K | 192.70K | 216.30K | 256.80K | 131.37K | 210.58K | 268.22K | 129.98K | 138.11K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 690.67K | 659.79K | 1.15M | 1.64M | 2.66M |
| Gross Profit | 148.25K | -56.29K | -119.33K | 215.19K | 567.45K |
| Net Income | -3.24M | -5.68M | -6.66M | -7.77M | -7.59M |
| Diluted EPS | - | -0.87 | -10.87 | -5.19 | -1.90 |
| R&D Expense | 86.26K | 524.69K | 662.18K | 819.39K | 725.39K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 824.32K | 4.69M | 6.22M | 9.84M | 10.14M |
| Total Equity | -554.84K | 207.52K | 4.02M | 5.56M | 9.10M | 9.07M |
| Cash & Equivalents | - | 79.73K | 3.59M | 4.29M | 2.63M | 6.51M |
| Total Liabilities | - | 616.80K | 665.46K | 659.94K | 743.17K | 1.07M |
| Current Liabilities | - | 616.80K | 600.00K | 624.49K | 737.72K | 1.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -1.21M | -3.22M | -5.77M | -6.74M | -7.28M |
| Investing Cash Flow | -118.45K | -219.95K | -198.75K | -5.16M | 4.48M |
| Financing Cash Flow | 1.39M | 6.96M | 6.66M | 10.24M | 6.68M |
| Capital Expenditure | -20.78K | -121.56K | -78.46K | -62.20K | -72.51K |
| Free Cash Flow | -1.23M | -3.35M | -5.84M | -6.80M | -7.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | 21.5% | -8.5% | -10.4% | 13.1% | 21.3% |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | -469.8% | -861.2% | -578.2% | -474.6% | -285.2% |
| ROE % | -1,563.5% | -141.2% | -119.9% | -85.4% | -83.7% |
| ROCE % | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cetera Investment Advisers | 6.71% | 577.35K | $548.37K |
| 2 | Xtx Topco Ltd | 0.48% | 41.00K | $38.94K |
| 3 | Citadel Advisors Llc | 0.34% | 29.60K | $28.11K |
| 4 | Keybank National Association | 0.23% | 20.00K | $19.00K |
| 5 | Geode Capital Management, LLC | 0.21% | 18.14K | $17.22K |
| 6 | HRT Financial LP | 0.15% | 12.63K | $12.00K |
| 7 | Jane Street Group, LLC | 0.14% | 12.13K | $11.52K |
| 8 | UBS Group AG | 0.06% | 5.19K | $4.92K |
| 9 | Tower Research Capital LLC (TRC) | 0.04% | 3.47K | $3.29K |
| 10 | Jones Financial Companies, L.L.L.P. | 0.01% | 614 | $583 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LUCY
Innovative Eyewear, Inc. Announces Exclusive Australia and New Zealand Distribution Partnership with Directed Electronics - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNaThwU19RTlJiQzNZbTVYSGU0elN3S1hpWGpLM19qWTVHMTR1ZW02ZkxVMVlRcGxKZHNpSmhBQWdFM1FsQlJ3clBRdjdsS2tNSjlEaVlHRy1VNXRobG9YdTJ0ZkhpSXB3ZVJRZjUtc204OVdUZE04S051WTNHZndmNnNNUDYzNURUdllYdk…
Innovative Eyewear(LUCY) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNTWVIVDd6RlQ3cGVtREdZeXdmOGFPdG51QVN6S3pZX0RVa1RwVkpyNnFzc2VVWktPbjNrWWVRZjNfTzNIQU5wVGd2MldMal9yU3J1cEI2Nk9FN2xfcjBKcENGbDVvMUZTeF9rQXVBZjJ5RkJKQ05veXdfb2xYZXRFejhkdlhMSklxTHJ4Yw…
LUCY Stock Slides After Volatile Spike Draws Trader Focus - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNRkhKV0RPRDl6V2NYOTZyTEpBeUl6anQtZVVaeXgxVWNYMk1lM3Y0UEh3M3VNTjZOeTR6dkRsMU9SRlFOcDhhLUhNMnhaWFlJOTR0cDJjbkNkcnp3YngtaVF6YXFTaUdhSjVPOW1kUWU3cFJRb3NIY0NtVDRxdEsxa3FuYw?oc=5" targe…
LUCY - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE45SlYxeWUyT0FKWHl3SkhOTkJmRENZaGVnWU93VTlXTHRkdHZWdTlOVWlqNGxTY0hlZlZlOG5VX1NmQVhMS2c?oc=5" target="_blank">LUCY</a> <font color="#6f6f6f">Finviz</font>…
Innovative Eyewear Surges After Preliminary Q2 Sales Jump and New Retail Wins | LUCY Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxPWklZeVFjZnBBZVg1aTFNSUV6cmJreVFzTWN0TkxveU1ONE40MkY2R3A5clJCckF3eklFNXB1eEt1WUxUR09Zb2FSU2R0R2lnNWNLZVV3MnVPV0NGcGdSS1JicGI4X05sMm1uOFhkWmk1bHloV0hNVlF3Y1JlZnE0QzY3WFlDeF9hWFV3Q0…
A smart-glasses test is set to reach 375 Canadian stores - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNcmhkZVJoOTJrOTEzMDllT0RwVHFLLVlDdUVyeGJIamFKRms4clU4WGRfcmhWM1R4dHRaMjJ2WkVJYXQtQmdDV2RXQTR5ekU1bzJKOTZhVHhTeU5qX1pWa1Z4dmw0QlF5Z1VKZ2d1M09tN3Nyd2JXS0tETERMak41OTV5VjI0RVROOFJCdz…
LUCY — Frequently Asked Questions
What is the current share price of Lucyd, Inc (LUCY)?
As of 2026-09-19 21:16 PDT, Lucyd, Inc (LUCY) trades at $0.87 on NasdaqCM. Its 52-week range is $0.65 to $2.20.
What is the market capitalisation of LUCY?
Lucyd, Inc (LUCY) has a market capitalisation of $7.49M on NasdaqCM.
What is the P/E ratio of LUCY?
LUCY trades at a trailing price-to-earnings (P/E) ratio of -0.75. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.88.
What is the return on equity (ROE) of LUCY?
LUCY has a return on equity (ROE) of -84.58%.
Is LUCY a good stock to buy?
This page provides a data-driven analysis of Lucyd, Inc (LUCY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.